| Dexamethasone in Hospitalized Patients with Covid-19 TRC Group* New England Journal of Medicine, 693-704, 2021 | 9723* | 2021 |
| Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis J Allotey, S Fernandez, M Bonet, E Stallings, M Yap, T Kew, D Zhou, ... bmj 370, 2020 | 2744 | 2020 |
| Global Tuberculosis Report 2020–Reflections on the Global TB burden, treatment and prevention efforts J Chakaya, M Khan, F Ntoumi, E Aklillu, R Fatima, P Mwaba, N Kapata, ... International journal of infectious diseases 113, S7-S12, 2021 | 1027 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 742* | 2021 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 565 | 2018 |
| Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases M Tadolini, LR Codecasa, JM García-García, FX Blanc, S Borisov, ... European Respiratory Journal 56 (1), 2020 | 528 | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 525* | 2021 |
| Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies S Tiberi, N du Plessis, G Walzl, MJ Vjecha, M Rao, F Ntoumi, S Mfinanga, ... The Lancet Infectious Diseases 18 (7), e183-e198, 2018 | 397 | 2018 |
| Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study SE Borisov, K Dheda, M Enwerem, RR Leyet, L D'Ambrosio, R Centis, ... European Respiratory Journal 49 (5), 2017 | 386 | 2017 |
| Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects D Visca, CWM Ong, S Tiberi, R Centis, L D’ambrosio, B Chen, J Mueller, ... Pulmonology 27 (2), 151-165, 2021 | 328 | 2021 |
| Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020 GB Migliori, PM Thong, O Akkerman, JW Alffenaar, F Álvarez-Navascués, ... Emerging infectious diseases 26 (11), 2709, 2020 | 246 | 2020 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 241 | 2020 |
| Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB S De Lorenzo, JW Alffenaar, G Sotgiu, R Centis, L D'Ambrosio, S Tiberi, ... European Respiratory Journal 41 (6), 1386-1392, 2013 | 212 | 2013 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 202 | 2019 |
| Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study I Abubakar, F Drobniewski, J Southern, AJ Sitch, C Jackson, M Lipman, ... The Lancet Infectious Diseases 18 (10), 1077-1087, 2018 | 202 | 2018 |
| New drugs and perspectives for new anti-tuberculosis regimens S Tiberi, M Muñoz-Torrico, R Duarte, M Dalcolmo, L D’ambrosio, ... Pulmonology 24 (2), 86-98, 2018 | 195 | 2018 |
| Direct whole-genome sequencing of sputum accurately identifies drug-resistant Mycobacterium tuberculosis faster than MGIT culture sequencing RM Doyle, C Burgess, R Williams, R Gorton, H Booth, J Brown, JM Bryant, ... Journal of clinical microbiology 56 (8), 10.1128/jcm. 00666-18, 2018 | 190 | 2018 |
| Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study GB Migliori, PM Thong, JW Alffenaar, J Denholm, M Tadolini, F Alyaquobi, ... European Respiratory Journal 58 (5), 2021 | 173 | 2021 |
| Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid … CWM Ong, GB Migliori, M Raviglione, G MacGregor-Skinner, G Sotgiu, ... European Respiratory Journal 56 (4), 2020 | 164 | 2020 |
| Clinical standards for the assessment, management and rehabilitation of post-TB lung disease GB Migliori, FM Marx, N Ambrosino, E Zampogna, HS Schaaf, ... The International Journal of Tuberculosis and Lung Disease 25 (10), 797-813, 2021 | 162 | 2021 |
Giovanni SotgiuUniversity of Sassari在 uniss.it 的电子邮件经过验证
